US · Healthcare · Biotechnology
EPS came in at -0.69 against a street estimate of -0.67 — a miss of 3.0%.
Analysts rate Tyra Biosciences Inc a strong buy (14 buy, 1 hold, 0 sell out of 15) with an average price target of $47.45.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 17.74% |
| FMR Inc | 12.97% |
| Jupiter Topco LLC | 6.33% |
| HHG PLC | 5.66% |
| Alta Partners Management Company, L.P. | 5.56% |
| Nextech Invest, Ltd. | 5.17% |
| TCG Crossover Management, LLC | 4.73% |
| BlackRock Inc | 4.41% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 TYRA BIOSCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company raising approximately $400.0 million in gross proceeds from a public offering • Offe | 2026-09-15 |
| Company announcement · Q3 2026 TYRA BIOSCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • SURF302 Phase 2 Study (Dabogratinib for Bladder Cancer): Overall Response Rate of 79% (11/14 | 2026-09-09 |
| Quarterly report · Q2 2026 TYRA BIOSCIENCES, INC. – 10-Q SUMMARY Period Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and marketable securities combined: $353.9 million as | 2026-08-04 |
| Results announced · Q3 2026 TYRA BIOSCIENCES Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and marketable securities: $353.9 million as of June 30 | 2026-08-04 |
| Shareholder vote results · Q2 2026 TYRA BIOSCIENCES, INC. — 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting Date: May 28, 2026 • Company Ticker: TYRA (Nasdaq Global Select Market) • Inc | 2026-06-02 |
| Quarterly report · Q1 2026 TYRA BIOSCIENCES, INC. — 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Cash and marketable securities: $383.5 million (cash $85. | 2026-05-13 |
| Results announced · Q2 2026 TYRA BIOSCIENCES Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and marketable securities: $383.5 million at March 31, 2026 • C | 2026-05-13 |
| Proxy statement · Q2 2026 TYRA BIOSCIENCES, INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 (Director Elections): Elect three Class II direct | 2026-04-17 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tyra Biosciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.